Browse by author
Lookup NU author(s): Dr Lars Klinge,
Professor Volker Straub
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Infantile Pompe disease (IPD) is a fatal, autosomal recessive muscle-wasting disorder. Due to a deficiency of the lysosomal enzyme acid alpha-glucosidase patients develop a generalized myopathy, diaphragmatic weakness, and cardiomyopathy leading to death usually within the first year of life. So far there is no therapy available. We report on the safety and efficacy of transgenically derived recombinant human precursor acid alpha-glucosidase (rhGAA) in a 10-month follow-up study in two children with IPD who previously completed a 48-week course of enzyme replacement therapy (ERT) with the same medication at the same dose in a phase II clinical trial. Under this therapy cardiac status and muscle strength had improved, leading to survival beyond the age of one year. These results, together with data from two other phase II clinical trials encouraged further evaluation of the long-term safety and efficacy of enzyme replacement therapy in patients with infantile-onset Pompe disease. During the 10-month follow-up period, ERT was well-tolerated and neither patient experienced a single infusion-associated reaction. The initial improvements in cardiac size and function, as measured by left ventricular mass index and the fractional shortening, were maintained in both patients, and a continued improvement of motor function, as measured by the Alberta infant motor scale, was observed. © Georg Thieme Verlag KG Stuttgart.
Author(s): Klinge L, Straub V, Neudorf U, Voit T
Publication type: Article
Publication status: Published
ISSN (print): 0174-304X
ISSN (electronic): 1439-1899
Publisher: Georg Thieme Verlag
PubMed id: 15776317
Altmetrics provided by Altmetric